Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An update from GlucoTrack ( (GCTK) ) is now available.
On January 30, 2025, Glucotrack, Inc. announced a 1-for-20 reverse stock split of its common stock, which will take effect on February 4, 2025. The move is intended to help the company comply with Nasdaq’s $1.00 minimum bid price requirement and potentially attract a broader range of institutional investors. The reverse stock split will reduce the number of outstanding shares from approximately 155.5 million to about 7.8 million, while the ownership percentage of each shareholder remains unchanged.
More about GlucoTrack
Glucotrack, Inc. is a medical device company that focuses on designing, developing, and commercializing innovative technologies for individuals with diabetes. The company is currently working on a long-term implantable continuous blood glucose monitoring system.
YTD Price Performance: -70.94%
Average Trading Volume: 45,463,521
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $1.47M
For detailed information about GCTK stock, go to TipRanks’ Stock Analysis page.
